Shares of Dr. Reddy's Laboratories Ltd. 500124 inched down 0.41% to 1,191.45 Indian rupees Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the BSE ...

Dr. Reddy's Laboratories Ltd. closed 11.64% short of its 52-week high of 1,377.95 rupees, which the company reached on June 12th.

Add Yahoo as a preferred source to see more of our stories on Google. SHREVEPORT, La. (KTAL/KMSS) – Dr. Reddy’s Laboratories, a global pharmaceutical company, recently closed in early 2025 due to ...

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the ...

The Indian drugmaker gave an oral undertaking to the Delhi High Court after Novo Nordisk alleged trademark infringement of its blockbuster semaglutide drug ‘Ozempic ...

View Dr. Reddy's Laboratories Ltd. Sponsored ADR RDY stock quote prices, financial information, real-time forecasts, and company news from CNN.

Stay updated with the Dr Reddys Stock Liveblog, your one-stop destination for real-time information and analysis of a leading ...

Dr Reddy's Share Price: Global Financial Services, Morgan Stanley has revised its outlook on Dr Reddy's Laboratories, ...

Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent stock. Keep track of Dr Reddys with the latest details, including: Last ...

Dr Reddy’s Lab targets ₹1,315 after launching a premium GLP-1 product, Obeda, positioning for growth in India’s market.